Is Preservation of Cholinergic Activation a Mechanism Underlying Cognitive Reserve?

Noriyuki Matsukawa*
Department of Neurology, Nagoya City University, Kawasaki, Mizuho-ku, Nagoya 467-8601, Japan

Abstract

The cognitive reserve, despite having abundant pathological change of Alzheimer’s disease, some patients can preserve cognitive function, is a new concept to puzzle Alzheimer’s pathogenesis. Interestingly, some recent epidemiological study has shown that diet, exercise, cognitive training and vascular risk monitoring interventions may reduce cognitive decline in at-risk elderly people in the general population. However, the mechanisms underlying this cognitive function preservation are still unknown. Our recent data suggest that differences in the persisting degree of cholinergic activity might be, at least in part, involved in the de-correlation between the extent of cognitive deterioration and AD pathological changes. This fact might raise a possibility of cholinergic modulation for hippocampal glutamatergic activity in a mechanism of “cognitive reserve”.

Previous research suggests that amyloid-β (Aβ) assemblies can inhibit glutamatergic neuronal activity in the hippocampus and increase neurofibrillary tangle (NFT) formation via phosphorylation of tau protein in Alzheimer’s disease (AD), forming the basis of the amyloid hypothesis [1]. However, several therapeutic interventions for reducing Aβ in patients with AD have failed to ameliorate the decline of cognitive function. Meanwhile, some patients have been reported to exhibit preserved cognitive function despite pathological changes in the brain; for example, a nun named Sister Mary maintained cognitive function within the normal range until just prior to death in spite of abundant senile plaques (SPs) and NFTs in the brain [2]. Other studies have reported that some individuals can tolerate more Alzheimer’s-related pathological changes than others, a phenomenon known as “cognitive reserve”. Epidemiological studies have suggested that a range of factors, including education (intelligence quotient: IQ), occupation, leisure activity, mental activity and exercise, could be involved in cognitive reserve [3]. However, the details of the molecular mechanisms underlying this cognitive functional preservation are still unknown.

Memory dysfunction is the main neurological sign in AD and the primary lesion is thought to be related to glutamatergic neuronal activity in the hippocampus. The synchronization of hippocampal neuronal oscillation through neural connections between the cortex and hippocampus via the subiculum is involved in memory function [4]. Glutamatergic activation in the hippocampus is modulated by several neuronal networks, including adrenergic and cholinergic neurons [5]. In the AD brain, glutamatergic neuronal activity may be impaired and incompletely suppressed by Aβ oligomers as glutamatergic neurons are in an unsaturated condition [6].

Interestingly, enriched environments have been found to prevent the impairment of hippocampal long term potentiation (LTP), the classical electrophysiological model of memory [7]. This process is thought to occur via β2-adrenergic signals, when LTP is incompletely suppressed by synthetic Aβ oligomers [7].

The modulatory effect of cholinergic activity on hippocampal synaptic plasticity may be concentration-dependent [8]. Interestingly, sub threshold cholinergic stimulation via low doses of a cholinergic agonist, can also enhance unsaturated glutamatergic activity in hippocampus, but not saturated LTP [9].

From the early stages of Alzheimer’s disease, the concentration of acetylcholine is decreased in the brain and the cholinergic neurons in the basal forebrain, medial septal nucleus and nucleus basalis of Meynert are degenerative; these findings have led to formation of the choline hypothesis [10]. Interestingly, cholinergic agonists, particularly the stimulation of the muscarinic M1 receptor, can, at least in part, prevent LTP impairment by synthetic Aβ oligomers as well as β2-adrenergic stimulants [9]. The effects of cholinergic activation on the amelioration of cognitive function via cholinesterase inhibitors have been confirmed in clinical settings, whereas cholinesterase inhibitors do not ameliorate memory function in individuals without dementia.

However, the effects of cholinesterase inhibitors are limited, and were found to disappear 10-12 months after beginning medication once cognitive function was ameliorated [11]. To utilize cholinergic activation for cognitive preservation for prolonged periods, the degenerative process of cholinergic neurons in the forebrain would need to be inhibited in the Alzheimer’s brain. Several neurotrophic factors have been proposed as candidates, including brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). However, the details of the underlying mechanisms of these factors in the human brain remain unclear.

Previously, we reported the importance of a cholinergic regulator gene in the medial septal nucleus (MSN) called hippocampal cholinergic neurostimulating peptide (HCNP) [12,13]. Recently, we demonstrated that cholinergic neural activation enhanced glutamatergic neuronal activity during unsaturated LTP, but not saturated LTP, using hippocampal sections from mice. Synthetic Aβ oligomers also suppressed the hippocampal glutamatergic activity in a concentration-dependent manner. Furthermore, HCNP over-expression as well as a cholinergic agonist, through the muscarinic M1 receptor, appeared
to prevent the suppression of hippocampal glutamatergic neuronal activity induced by synthetic Aβ oligomers [9].

Our data suggest that the neural modulation network projecting hippocampal glutamatergic activation, including cholinergic as well as β2-adrenergic nerve fibers, could play at least a partial role in the mechanisms underlying cognitive reserve. The clinical fact, cholinesterase inhibitors could ameliorate memory function in only patients with AD, in not individuals without dementia, might also accord with our experimental event that cholinergic stimulation can only enhance unsaturated glutamatergic activity in hippocampus, but not saturated it. These findings indicate that preservation of cholinergic neurons in the forebrain in the AD brain might be a new therapeutic target for treating Alzheimer’s disease.

Conclusion

Differences in the persisting degree of cholinergic activity might be involved in the decorrelation between the extent of cognitive deterioration and AD pathological changes. In addition, the mechanisms of cognitive decline in late-onset sporadic AD should be reconsidered based on clinical and epidemiological findings indicating the involvement of cholinergic activation, diabetes mellitus, atrial fibrillation and/or head trauma, as well as Aβ oligomers.

References

1. Serwer P (2018) Hypothesis for the cause and therapy of neurodegenerative disease. Med Hypotheses 110: 60-63.
2. Snowdon DA (1997) Aging and Alzheimer’s disease: Lessons from the nun study. Gerontologist 37: 150-156.
3. Stern Y (2012) Cognitive reserve in aging and Alzheimer’s disease. Lancet Neurol 11: 1006-1012.
4. Gu Z, Yakel JL (2011) Timing-dependent septal cholinergic induction of dynamic hippocampal synaptic plasticity. Neuron 71: 155-165.
5. Lewis PR, Shute CC (1967) The cholinergic limbic system: Projections to hippocampal formation, medial cortex, nuclei of the ascending cholinergic reticular system and the subfimbrial organ and supra-optic crest. Brain 90: 521-540.
6. Patel AN, Jhamandas JH (2012) Neuronal receptors as targets for the action of amyloid-beta protein (Aβ) in the brain. Expert Rev Mol Med 14: e2.
7. Li S, Jin M, Zhang D, Yang T, Koeglsperger T, et al. (2013) Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by Abeta oligomers. Neuron 77: 929-941.
8. Auerbach JM, Segal M (1994) A novel cholinergic induction of long-term potentiation in rat hippocampus. J Neurophysiol 72: 2034-2040.
9. Sato T, Ohi Y, Kato D, Mizuno M, Takase H, et al. (2017) Hippocampal cholinergic neurostimulating peptide as a possible modulating factor against glutamatergic neuronal disability by amyloid oligomers. Cell Transplant 26: 1542-1550.
10. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, et al. (1982) Alzheimer’s disease and senile dementia: Loss of neurons in the basal forebrain. Science 215: 1237-1239.
11. Takeda A, Loverman E, Clegg A, Kirby J, Picot J, et al. (2006) A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int J Geriatr Psychiatry 21: 17-28.
12. Ojika K, Kojima S, Ueki Y, Fukushima N, Hayashi K, et al. (1992) Purification and structural analysis of hippocampal cholinergic neurostimulating peptide. Brain Res 572: 164-171.
13. Ojika K, Mitake S, Tohdoh N, Appel SH, Otsuka Y, et al. (2000) Hippocampal cholinergic neurostimulating peptide (HCNP). Prog Neurobiol 60: 37-83.